IMU’s discovery engine maps the immune system in unprecedented detail and scale to deliver unique, systems-level immune insights.
Use our platform today to measure +2,000 discrete cell subset capturing systems-level immune profiles, to power in-depth disease modeling, drug development, patient monitoring, and translational research
IMU is unlocking the potential of the immune system. Through innovative and comprehensive systems-level immunophenotyping and advanced AI and ML analytics, IMU is generating, harmonising and translating vast system-level immune data into actionable insights and tools to drive the development of precision medicine across a range of health conditions and treatment responses.
Our mission at IMU is to develop groundbreaking, population-scale systems-level understanding of the immune system. By leveraging the power of ML and AI analytics, combined with our high resolution immune profiling platform, we are creating tools that offer unprecedented insights into disease and health. This approach is essential for unlocking the immense potential of the immune system and advancing the development of precision immune medicines.
We are a team of healthcare experts, immunologists, clinicians, technologists, developers and researchers with a bold ambition: to transform our understanding of the immune system and advance precision immune medicine.
IMU is founded on the belief that leveraging deep, systems-level immunophenotyping at a population scale, combined with the latest advancements in AI and ML, is essential for unlocking the immense potential of the immune system as a tool in the development of precision immune medicines.
We are driven by the belief that in the future, no medical decision will be made without truly understanding a patient's immune system, heralding a new era of precision healthcare.
We’re a team of healthcare experts, immunologists, clinicians, technologists, developers and researchers with a bold ambition: To transform our understanding of the immune system and advance precision medicine.
IMU is collaborating with leading pharmaceutical companies, research organisations and academic institutions, applying our technology across health and disease to advance translational research and accelerate precision drug development.
IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine
London, UK, 24 January 2024 — IMU Biosciences (or “the Company”), a techbio company revolutionising immune powered precision medicine, today announces the close of a £11.5 million Series A financing round. The round was led by European tech VC Molten Ventures and included LifeX Ventures and other individuals.
PRESS RELEASE: IMU secures £10 million in Series A funding to revolutionise our understanding of the immune system. Read more >